The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis
| Autor: | Vanaja Kanamaluru, Brad Shumel, John D. Davis, Yi Zhang, Pavel Kovalenko, Nidal Al-Huniti, Manoj Rajadhyaksha, Eric L. Simpson, Mohamed A. Kamal, Matthew P. Kosloski, Elaine C. Siegfried, Kamal Srinivasan, Xian Sun, Ashish Bansal, Ching Ha Lai, Christine Xu, Amy S. Paller |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Placebo Antibodies Monoclonal Humanized Dermatitis Atopic Pharmacokinetics Double-Blind Method Internal medicine Medicine Humans Pharmacology (medical) In patient Child Pharmacology Dose-Response Relationship Drug business.industry Interleukin-4 Receptor alpha Subunit Atopic dermatitis medicine.disease Dupilumab Regimen Baseline weight Concomitant Female business Follow-Up Studies |
| Zdroj: | Clinical pharmacology and therapeutics. 110(5) |
| ISSN: | 1532-6535 |
| Popis: | Dupilumab demonstrated efficacy with an acceptable safety profile in two randomized, double-blind, placebo-controlled, parallel-group, phase III trials in adolescents (12-17 years; LIBERTY AD ADOL) and children (6-11 years; LIBERTY AD PEDS) with atopic dermatitis (AD) treated for 16 weeks. Here, we present the pharmacokinetic profiles and exposure-response relationships of dupilumab that guided the posology in these populations. A total of 251 adolescent patients with moderate-to-severe AD were randomized to subcutaneous dupilumab monotherapy every 2 weeks (q2w) (200 mg q2w, baseline weight |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text